Skip to main content
. 2021 Feb 9;10:e9. doi: 10.1017/jns.2020.61

Table 1.

Characteristics of patients with type 2 diabetes mellitusa

Variables Apo A-II genotype
CC TT + TC
Number of participants, n (%) 94 (12⋅1) 684 (87⋅9)
Age (year) 55 ± 6 54 ± 7
Male/ Female, n (%) 37/57 (39⋅4/60⋅6) 268/415 (39⋅2/60⋅8)
Smoking, Yes/No, n (%) 10/84 (10⋅6/89⋅4) 138/545 (20⋅2/79⋅8)
Physical activity (MET h/d) 36⋅96 ± 1⋅12 37⋅33 ± 1⋅15
Medical history
 Diabetes duration (≤5 years), n (%) 35 (37⋅2) 305 (44⋅7)
 Diabetes duration (>5 years), n (%) 59 (62⋅8) 378 (55⋅3)
History of CVD, Yes/No, n (%) 37/57 (39⋅4/60⋅6) 256/427 (37⋅5/62⋅5)
Supplement use, Yes/No, n (%)b 47/47 (50/50) 333/345 (49⋅1/50⋅9)
Lipid-lowering medication, Yes/No, n (%)c 56/38 (59⋅6/40⋅4) 390/292 (57⋅2/42⋅8)
Glucose-lowering medication, Yes/No, n (%)d 88/6 (93⋅6/6⋅4) 635/48 (93/7)
Food intake
Energy (kcal/d) 2416⋅31 ± 1⋅43 2465⋅13 ± 1⋅37
Carbohydrate (g/d) 323⋅75 ± 1⋅46 320⋅53 ± 1⋅40
Protein (g/d) 83⋅93 ± 1⋅46 84⋅77 ± 1⋅39
Fat (g/d) 92⋅75 ± 1⋅53 94⋅63 ± 1⋅53
Fibre (g/d) 40⋅04 ± 1⋅53 38⋅09 ± 1⋅55
Dietary total antioxidant capacity
FRAP (mmol Fe2+/100 g) 15⋅48 ± 3⋅27 15⋅48 ± 3⋅18
TRAP (mmol TE/kg) 8⋅00 ± 1⋅35 8⋅67 ± 1⋅58
TEAC (mmol TE/kg) 7⋅38 ± 1⋅49 7⋅84 ± 1⋅52
ORAC (μmol TE/100 g) 28 853⋅88 ± 1⋅50 27 722⋅57 ± 1⋅44

Abbreviations: CVD, cardiovascular disease; MET, metabolic equivalents; FRAP, ferric reducing ability of plasma; TRAP, total reactive antioxidant potential; TEAC, Trolox equivalent antioxidant capacity; ORAC, oxygen radical absorbance capacity.

a

All data are mean ± sd unless indicated.

b

Supplements of vitamins and minerals.

c

Statins, gemfibrozil and nicotinamide.

d

Metformin, glibenclamide and thiazolidionedione.